

[54] PLASMINOGEN ACTIVATOR DERIVATIVES

[76] Inventors: Kimihiro Shimizu, Yoshikawa-danchi 4-16-102, Yoshikawa-machi, Kitakatsushika-gun, Saitama-ken; Tsuguji Nakahara, 6-21-6, Megurohonmachi, Meguro-ku, Tokyo; Taketoshi Kinoshita, Satsuki-so, Noborito 15-30, Koshigaya-shi, Saitama-ken, all of Japan

[21] Appl. No.: 437,009

[22] Filed: Oct. 27, 1982

[30] Foreign Application Priority Data

Oct. 30, 1981 [JP] Japan ..... 56-172908

[51] Int. Cl.<sup>3</sup> ..... C12N 9/72; C12N 9/48; C12N 11/06

[52] U.S. Cl. .... 435/215; 435/212; 435/181

[58] Field of Search ..... 435/181, 212, 215

[56] References Cited

U.S. PATENT DOCUMENTS

4,179,337 12/1979 Davis et al. .... 435/181  
4,349,630 9/1982 Maximenko et al. .... 435/215 X

OTHER PUBLICATIONS

Kenneth J. Weider et al., "Some Properties of Polyethylene Glycol: Phenylalanine Ammonia-Lyase Adducts", J. Biol. Chem. 254 (24): 12579-12587 (1979).  
Stephen Davis et al., "Hypouricaemic Effect of Poly-

ethylene Glycol Modified Urate Oxidase", The Lancet, Aug. 8: 281-283 (1981).

Kenneth V. Savoca et al., "Preparation of a Non-immunogenic Arginase by the Covalent Attachment of Polyethylene Glycol", Biochim. Biophys. Acta, 578: 47-53 (1978).

Peter S. Pyatak et al., "Preparation of a Polyethylene Glycol: Superoxide Dismutase Adduct, and an Examination of its Blood Circulating Life and Anti-inflammatory Activity", Res. Commun. Chem. Pathol. Pharmacol., 29(1): 113-127 (1980).

Robert H. L. Chen et al., "Properties of Two Urate Oxidases Modified by the Covalent Attachment of Poly(Ethylene Glycol)", Biochim., Biophys. Acta, 660: 293-298 (1981).

Abraham Abuchowski et al., "Immunosuppressive Properties and Circulating Life of Achromobacter Glutaminase-Asparaginase Covalently Attached to Polyethylene Glycol in Man", Cancer Treat. Rep., 65: 11-12 (1981).

Primary Examiner—Lionel M. Shapiro

[57] ABSTRACT

A derivative of a human-originated non-immunogenic plasminogen activator is disclosed which comprises at least one polyalkylene glycol attached with at least one coupling agent to amino acid side chains of said plasminogen activator, said polyalkylene glycol having a molecular weight of 200-20,000 and optionally containing one or more alkyl and/or alkanoyl groups as substituents. Also disclosed are a process for producing such derivative and a thrombolytic agent containing such derivative.

17 Claims, 7 Drawing Figures